Pedilid150 mg

Pedilid 150 mg is a macrolide antibiotic used to treat bacterial infections caused by susceptible organisms, including:

Respiratory Tract Infections

• Acute and chronic bronchitis
• Community-acquired pneumonia, including atypical pneumonia caused by Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella species
• Pharyngitis and tonsillitis (as an alternative in patients unable to take penicillin)
• Sinusitis

Skin and Soft Tissue Infections

• Skin and soft tissue infections caused by susceptible organisms

Genital Infections

• Uncomplicated genital infections caused by Chlamydia trachomatis, in some treatment guidelines

Dental Infections

• Odontogenic (dental-origin) infections, in some markets, as an alternative for penicillin-allergic patients

Pedilid 150 mg is not effective against viral infections and should only be used for infections confirmed or strongly suspected to be bacterial.

Contains Pedilid 150 mg as the active ingredient, available as oral film-coated tablets, commonly in 150 mg and 300 mg strengths.

Pedilid 150 mg is a semi-synthetic macrolide antibiotic, chemically related to erythromycin but with improved gastrointestinal tolerability, better tissue penetration, and a longer half-life that allows twice-daily (or once-daily at higher strength) dosing. It is commonly used for respiratory tract infections, including atypical pneumonia caused by organisms that do not respond to penicillin-type antibiotics, as well as certain skin and soft tissue infections. It is often chosen as an alternative for patients who are allergic to penicillin.

Therapeutic Class: Antibiotic (Macrolide)

Pedilid 150 mg is well absorbed orally, with peak plasma concentrations reached about 2 hours after dosing; absorption is reduced if taken after food, which is why it is directed to be taken before meals. It achieves good tissue and intracellular concentrations, particularly in the respiratory tract, which supports its effectiveness against atypical respiratory pathogens. It has a longer elimination half-life (approximately 10-12 hours) than erythromycin, supporting twice-daily dosing, and is eliminated primarily via the bile and, to a lesser extent, the kidneys.

• Take at least 15 minutes before a meal, since food significantly reduces absorption
• Swallow the tablet whole with a full glass of water
• Take doses at evenly spaced intervals (approximately every 12 hours for twice-daily dosing)
• Complete the full prescribed course, even if symptoms improve before the course is finished

Pedilid 150 mg has a lower potential for certain drug interactions than erythromycin (since it has less effect on the CYP3A4 enzyme), but the following should still be assessed by a healthcare professional:

• Ergot alkaloids (such as ergotamine and dihydroergotamine): combining with macrolides has been associated with ergotism (severe peripheral vasospasm and ischemia); this combination should generally be avoided.
• Warfarin and other anticoagulants: macrolides may enhance anticoagulant effect in some patients; more frequent INR monitoring is advisable if Pedilid 150 mg is started or stopped during warfarin therapy.
• Theophylline: Pedilid 150 mg has a lower interaction potential than erythromycin, but concurrent use has still been associated with mild increases in theophylline levels in some patients; monitoring is reasonable, particularly at higher theophylline doses.
• Ciclosporin: macrolides can increase ciclosporin blood levels; monitoring of ciclosporin levels is advisable if used together.
• Digoxin: macrolides can increase digoxin absorption by altering gut flora that normally metabolize digoxin, raising digoxin blood levels; monitoring is advisable.
• Other QT-prolonging medicines: macrolides as a class have been associated with QT interval prolongation in susceptible patients; caution is advised when combined with other drugs that prolong the QT interval.

Common side effects

• Nausea, vomiting
• Diarrhoea or abdominal discomfort
• Headache
• Altered taste sensation

Serious side effects (seek medical attention)

• Severe or persistent diarrhoea, which may indicate Clostridioides difficile-associated colitis
• Signs of liver problems: yellowing of the skin or eyes, dark urine, severe abdominal pain
• Signs of a severe allergic reaction: rash, swelling of the face or throat, difficulty breathing
• Signs of a heart rhythm problem: palpitations, dizziness, fainting
• Severe skin reactions: blistering, peeling skin

Pregnancy

Data on Pedilid 150 mg use in human pregnancy are more limited than for some other macrolides; it should be used during pregnancy only if a doctor determines it is clearly necessary, weighing the potential benefit against limited safety data.

Breastfeeding

Pedilid 150 mg is excreted in breast milk in small amounts; use during breastfeeding should be discussed with a healthcare professional, considering the mother's clinical need for treatment.

• Complete the full prescribed course of treatment, even if symptoms improve early, to fully clear the infection and reduce the risk of antibiotic resistance.
• Take before meals, since food significantly reduces absorption and could compromise effectiveness if taken inconsistently with food.
• Use with caution in patients with hepatic impairment, given Pedilid 150 mg's hepatic elimination; avoid in severe impairment.
• Use with caution in patients with known QT prolongation or those on other QT-prolonging medicines.
• If diarrhoea develops during or after treatment, medical evaluation for Clostridioides difficile-associated diarrhoea should be considered, particularly if severe or persistent.

Overdose of Pedilid 150 mg may cause exaggerated gastrointestinal effects such as nausea, vomiting, and diarrhoea. Suspected overdose should be evaluated by a healthcare professional; treatment is generally supportive, provided in a medical facility, with monitoring of liver function and cardiac rhythm if a significant overdose is suspected.

Store at room temperature, below 25-30°C, away from moisture and excess heat, as directed on the product label. Keep out of reach of children.

• Elderly: No significant dose adjustment is generally required for age alone, though attention to hepatic and renal function is reasonable.
• Renal impairment: Pedilid 150 mg is mainly eliminated via bile; modest dose adjustment may be considered in severe renal impairment, per the prescribing physician.
• Hepatic impairment: Use with caution, since Pedilid 150 mg is significantly eliminated via the liver; avoid in severe hepatic impairment.

Treatment duration is typically 5-10 days for most respiratory tract, skin, and soft tissue infections, though atypical pneumonia or complicated infections may require a longer course, as determined by the treating physician. The full prescribed course should be completed even if symptoms resolve earlier.

Drug Class: Macrolide antibacterial

Pedilid 150 mg works by binding to the 50S ribosomal subunit of susceptible bacteria, blocking bacterial protein synthesis. This bacteriostatic action (inhibiting bacterial growth and reproduction rather than directly killing the bacteria at typical concentrations) allows the immune system to clear the infection, and can be bactericidal against some highly susceptible organisms at higher concentrations.

Pedilid 150 mg is used in children for susceptible bacterial infections, with weight-based dosing (commonly 5-8 mg/kg/day in two divided doses) determined by the treating physician; it is taken before meals, similar to the adult regimen.